Rohan Garje, MD
@RohanGarjeMD
Followers
650
Following
2K
Media
29
Statuses
443
Associate Professor, Chief of Genitourinary Medical Oncology, Miami Cancer Institute, Baptist Health
Miami, FL
Joined November 2020
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
15
89
204
🎶 Wondering how to tackle variant histologies in bladder cancer? Think of them as music genres—same stage, different openers (neoadj.) and headliners (1st line tx). 🎤 From micropapillary to plasmacytoid—each has a style & strategy. 🎧 Watch here ⬇️ @Uromigos @Dr_Aggen
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer.
0
13
22
@ASCO Guideline Clinical Insights: Systemic therapy in mCRPC, released Sept 4, 2025. Thanks to @rohangarjeMD, Dr. Rahul Parikh, @IrbazRiaz, and Dr. Arsalan Naqvi for their leadership on this article.
1
4
15
@ASCO updates #mCRPC guidelines for the first time in 10 years. Emphasis on individualized care, ongoing ADT, & #BiomarkerTesting. Key trials include MAGNITUDE, TALAPRO-2, and PROpel. @RohanGarjeMD: “This represents a shift toward #PrecisionOncology.”
oncologynewscentral.com
In May, ASCO updated its guidelines for metastatic castration-resistant prostate cancer to reflect data from key trials such as MAGNITUDE, TALAPRO-2, and PROpel.
0
2
8
The Updated ASCO Guidelines on Metastatic Castration-Resistant Prostate Cancer - @RohanGarjeMD
@BryanRumble @ASCO
https://t.co/G4KZKRZmb6
#Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer #CancerWorld #ASCO #mCRPC
oncodaily.com
Rohan Garje: The Updated ASCO Guidelines on Metastatic Castration-Resistant Prostate Cancer / Alan H. Bryce, Andrew Loblaw, Arnab Basu, ASCO, Baptist Health
0
3
16
📣Out now #ASCOGuidelines Update: Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update | Journal of Clinical Oncology https://t.co/3BBBspaeK2
#pcsm @ASCO @RohanGarjeMD
ascopubs.org
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO...
0
5
13
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer @ASCO Guideline Update https://t.co/n712hb1TWo The updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant
0
33
73
🚨 New @ASCO Guideline on #mCRPC just published! Glad to co-author recs on sequencing, #PARP inhibitors, #genomics, chemo & radiopharmaceuticals Grateful to expert panel @BryanRumble @IrbazRiaz #RahulParikh @AlanBryce9 @JCO_ASCO @OncoAlert @OncLive 🔗 https://t.co/eDA6j6VewH
0
15
49
ASCO 2024 mCRPC Update: 🙌 Put patients first: tailor to comorbidities, life expectancy & access 🧬 Genomic testing (BRCA1/2, HRR, MSI, TMB) = must 🧬 PARP inhibitors: for BRCA1/2, maybe others ☢️ Lu-PSMA: for PSMA+ after ARPI & chemo ❌ No ARPI after ARPI—unless no options
2
42
104
FDA expands the indication for a treatment for metastatic castration-resistant prostate cancer https://t.co/lvAmVkZ1jR
0
17
27
If you can get it (especially in 🇺🇸), can't argue with the cost of BCG: 1 yr, $1800 👇 #EAU25 debate -- @GGiannarini making the point that BCG is still the best option for HR NMIBC @urotoday Discussing @EUplatinum paper from Scilipoti, @UroMoschini @UrogerliMD @spsutkaMD
3
28
65
@binaytara @UHhospitals @maughanonc @huntsmancancer @WinshipAtEmory @bilenma @ZakhariaYousef @arnabguonc @kansalrohit69 @RohanGarjeMD @CParkMD in the room already thinking of the next trial in GU tumors
1
2
6
⭐️Dr. Pedro Barata gives a very thoughtful discussion of how to navigate 1st line RCC data in 2025 to provide best care for our patients. LOVE the updated table below. #AtlantaGU25
@binaytara @ZakhariaYousef @bilenma @RohanGarjeMD @BaptistHealthSF
@WinshipAtEmory @binaytara
1
9
20
#AtlantaGU25 starting with prostate cancer. Chaired by @WinshipAtEmory Dr Brad Carthon. Lots of updates in both the metastatic hormonal sensitive and castrate resistant spaces with @CParkMD and @RohanGarjeMD. @binaytara
0
8
24
👏 We kick off #AtlantaGU25 with @CParkMD from @Norton_Health, @RohanGarjeMD from @BaptistHealthSF and Dr. Louis Crain Garrot from Georgia Cancer Specialists discussing #prostatecancer 🔬. Session Chair: Dr. Bradley Carthon from @WinshipAtEmory. 🌟 Visit https://t.co/i1EG9demS7
0
4
15
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A https://t.co/12wSpPBxkJ ASCO released a rapid recommendation update on lutetium-177 (177Lu)-PSMA-617 for treating metastatic
2
18
33
Excited to co-chair this first GU summit with @bilenma in Atlanta with great lineup of speakers @PBarataMD @CParkMD @RohanGarjeMD @maughanonc @binayshah @arnabguonc @virajmaster @DocMattCampbell @BasselNazha and many more can’t find on X, 15 travel grants offered to trainees.
📅 Join us at the Atlanta Genitourinary Cancers Summit on Mar. 15, co-chaired by Winship medical oncologist Mehmet Asim Bilen, MD, and Mayo Clinic's Yousef Zakharia, MD. Experts will discuss advancements in prostate, kidney, bladder cancers and more. ➡️ https://t.co/rpe4LAULYQ
3
19
61
🧬 Liquid Biopsy in Clinical Practice: Past, Present & Future🩸 A new review explores the evolution, applications, and future directions of liquid biopsy in oncology. Here are the key insights: 🔬Technologies & Biomarkers ✅ Circulating Tumor Cells (CTCs) – Enrichment &
2
39
92
Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium @RohanGarjeMD @TDorffOnc @sonpavde @BradMcG04 @MDAndersonNews @MiamiCancerInst @UofGlasgow @cityofhope @DanaFarber @ASCO #GU25 #pcsm #blcsm #kcsm
https://t.co/xBujzYKXnd
onclive.com
Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.
0
1
4
Happy to present our research on prostate and urethral cancers @ASCO #GU25. Proud of my mentee @ganiyani_md who received merit 🥇 for his work!
4
6
45